Connect with us

Hi, what are you looking for?


Should you buy Walgreens stock on market-beating Q1 results?

Walgreens Boots Alliance Inc (NASDAQ: WBA) ended roughly 5.0% down even though it reported better-than-expected results for its first financial quarter.

Is Walgreens stock a ‘buy’?

Shareholders were put off by $5.2 billion of charge related to an opioid settlement that pushed it into a net loss this quarter.

But that doesn’t matter much to G Squared Private Wealth’s Victoria Greene. Recommending buying Walgreens stock on CNBC’s “Power Lunch”, she said:

They’re pivoting from a pharmacy to total health. This company is evolving. Their earnings weren’t bad minus the one-off items. For me, it’s a buy as I see potential in the stock and I see revenue streams continuing to grow.

At close to 8 times forward, Greene added, shares of the Deerfield-headquartered firm are reasonably priced as well.

Walgreens Q1 financial highlights

Lost $3.70 billion that translates to $4.31 a share

That compared to $3.6 billion profit a year ago

On an adjusted basis, earned $1.16 per share

Sales also slid from $33.9 billion to $33.4 billion

Consensus was $1.14 of EPS on $32.9 billion sales

Other notable figures and future guidance

Other notable figures in the earnings press release include a 3.0% hit to the U.S. Retail Pharmacy sales. U.S. Healthcare unit brought in $989 million in total this quarter.

For the full financial year, Walgreens Boots Alliance continues to expect up to $137.5 billion in sales on $4.45 a share to $4.65 a share of earnings.

Versus its high in late November, Walgreens stock is down roughly 16% at writing.

The post Should you buy Walgreens stock on market-beating Q1 results? appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Reprinted from the Future of Freedom Foundation President Biden’s campaign to banish (or maybe outlaw) political paranoia took a wallop last spring. In April,...


    Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...

    Editor's Pick

    It’s already a cliché, but technology is rapidly improving. And for many businesses, it’s hard to catch up. However, it’s not just the average...

    Editor's Pick

    At Broadband World Forum 2022, Fibocom launched 5G module FG370 based on MediaTek T830 platform, aiming to empower the deployment of 5G FWA for...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.